Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope

Marilyn M. Cox, Bruce A. Perlman, Manuel R. Mayor, Todd A. Silberstein, Ester Levin, Lynn Pringle, Agustin Castellanos, Robert J. Myerburg

Research output: Contribution to journalArticle

116 Scopus citations

Abstract

Objectives. This study was designed to prospectively evaluate the long-term outcome of drug therapy guided by head-up tilt testing for the management of unexplained syncope and near syncope. Background. Head-up tilt testing is used to evaluate patients with unexplained syncope. The validity of acute drug testing and the efficacy of long-term oral therapy for prevention of recurrent syncope have not been investigated in large patient groups. Methods. We studied 296 consecutive patients with unexplained syncope or near syncope who underwent 80° head-up tilt testing with and without isoproterenol challenge. The efficacy of intravenous and oral beta-blocker therapy was evaluated by repeat testing. Patients with both positive and negative responses to therapy were followed up for rates of recurrence of syncope. Results. A total of 193 patients (65%) had a positive tilt test response; 89% of these 193 required isoproterenol challenge to elicit this response. Patients with a positive tilt test result had lower values for heart rate at rest (mean ± SD 69 ± 13 vs. 74 ± 14 beats/min, p = 0.046) and systolic blood pressure (137 ± 28 vs. 145 ± 30 mm Hg, p = 0.0018) at baseline than did the patients with a negative tilt test result. Intravenous propranolol blocked the positive response in 163 (90%) of 181 patients retested. Oral beta-blockers were effective by tilt test criteria in 118 (94%) of 125 patients; 12 (10%) had recurrent clinical symptoms while taking beta-blockers. Eight (42%) of 19 patients who had a negative tilt test response during beta-blocker therapy had recurrent when they stopped therapy. Three (23%) of 13 patients receiving empiric beta-blocker therapy had recurrent symptoms. The follow-up period for the patients with a positive tilt test result was 28 ± 11 months (range 5 to 48). Conclusions. Intravenous propranolol is effective in preventing neurocardiogenic syncope diagnosed during head-up tilt testing and predicts the response to oral beta-blocker therapy. Oral beta-blocker therapy prevents recurrent syncope in the majority of patients. Recurrence of syncope is lowest when efficacy of oral beta-blocker therapy is confirmed by repeat head-up tilt testing.

Original languageEnglish (US)
Pages (from-to)1293-1298
Number of pages6
JournalJournal of the American College of Cardiology
Volume26
Issue number5
DOIs
StatePublished - Nov 1 1995

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope'. Together they form a unique fingerprint.

  • Cite this

    Cox, M. M., Perlman, B. A., Mayor, M. R., Silberstein, T. A., Levin, E., Pringle, L., Castellanos, A., & Myerburg, R. J. (1995). Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. Journal of the American College of Cardiology, 26(5), 1293-1298. https://doi.org/10.1016/0735-1097(95)00320-7